Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group

Targeted Oncology

Volumn 11, Issue 3, 2016, Pages 277-292

  Sodergren, Samantha C ^a   Copson, Ellen ^a   White, Alice ^a   Efficace, Fabio ^b   Sprangers, Mirjam ^c   Fitzsimmons, Deborah ^d   Bottomley, Andrew ^e   Johnson, Colin D ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b GIMEMA Data Center   (Italy)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d SWANSEA UNIVERSITY   (United Kingdom)

^e EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LAPATINIB; NERATINIB; PERTUZUMAB; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ANEMIA; ANOREXIA; ARTHRALGIA; BACKACHE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHILL; CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; CONSCIOUSNESS DISORDER; CONSTIPATION; CONSULTATION; COUGHING; DECREASED APPETITE; DEHYDRATION; DEPRESSION; DIARRHEA; DIZZINESS; DRY SKIN; DYSPNEA; EPISTAXIS; EYE JAUNDICE; FATIGUE; FEVER; FRACTURE; GASTROINTESTINAL DISEASE; HAIR COLOR DAMAGE; HAIR DISEASE; HAIR LOSS; HEADACHE; HEPATITIS; HOT FLUSH; HUMAN; HYPERTENSION; HYPONATREMIA; INDIGESTION; INFECTION; JAUNDICE; KIDNEY FAILURE; LABORATORY TEST; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKOCYTOCLASTIC VASCULITIS; LEUKOPENIA; LIP DISEASE; LIP NUMBNESS; LIVER FAILURE; LUNG EDEMA; METASTASIS POTENTIAL; MONOTHERAPY; MOUTH PAIN; MOUTH ULCER; MUCOSAL DISEASE; MUSCLE CRAMP; MUSCLE SPASM; MUSCULOSKELETAL PAIN; NAIL INFECTION; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PARESTHESIA; PHYSICAL ACTIVITY; PILOT STUDY; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; SIDE EFFECT; SKIN DISCOLORATION; SKIN MANIFESTATION; SKIN SORE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WEAKNESS; WEIGHT REDUCTION; XEROSTOMIA; BREAST NEOPLASMS; COMPLICATION; FEMALE; PSYCHOLOGY;

BREAST NEOPLASMS; FEMALE; HUMANS; QUALITY OF LIFE; RECEPTOR, ERBB-2;

EID: 84949945164     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-015-0409-2     Document Type: Review

References (48)

1. Widakowich CCGJ, de Azambuja E, Dinh P, Awada A (2007) Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 12(12):1443–1455
2. Slamon D, Godolphin W, Jones LA, Holt JA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712
3. Cobleigh M, Vogel C, Tripathy D, Robert N, Scholl S, Fehrenbacher L, Wolter J, Paton V, Shak S, Lieberman G, Slamon D (1999) Multinational study of the efficacy and safety of humanized anti-HERs monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9):2639–2648
4. Goldhirsch A, Coates AS, Gelber RD et al (2006) First—select the target: Better choice of adjuvant treatments for breast cancer patients. Ann Oncol 17:1772–1776
5. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M, Neo AST (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 9816:633–640
6. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28(7):1124–1130
7. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28(7):1138–1144. doi:10.1200/JCO.2009.24.2024
8. Portera CC, Walshe JM, Rosing DR, Denduluri N, Berman AW, Vatas U, Velarde M, Chow CK, Steinberg SM, Nguyen D, Yang SX, Swain SM (2008) Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 14(9):2710–2716. doi:10.1158/1078-0432.ccr-07-4636
9. Cortés J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross GA, Dixon J, Szado T, Baselga J (2012) Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30(14):1594–1600
10. Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T (2012) A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 133 (3):1057–1065.
11. Martin M, Bonneterre J, Geyer CE, Jr., Ito Y, Ro J, Lang I, Kim S-B, Germa C, Vermette J, Wang K, Wang K, Awada A (2013) A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer 49 (18):3763–3772.
12. Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al (2005) Trastuzumab after Adjuvant Chemotherapy in HER2 - Positive Breast Cancer. N Engl J Med 353(16):1659–1672
13. Lamot C, Rottey S, De Backer T, Van Bortel L, Robays H, Van Belle S, Denys H, Cocquyt V (2010) Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium. Acta Clin Belg 65(5):300–304
14. Al-Dasooqi N, Bowen JM, Gibson RJ, Sullivan T, Lees J, Keefe DM (2009) Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients. Investig New Drugs 27(2):173–178
15. Centre for Reviews and Dissemination (2009) Systematic reviews: CRD's guidance for undertaking reviews in health care. http://www.york.ac.uk.
16. Moher D, Liberati A, Tetzlaff J, Altman D (2009) The PG (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7):e1000097. doi:10.1371/journalpmed1000097
17. Sodergren SC WA, Efficace F, Sprangers M, Fitzsimmons D, Bottomley A, Johnson CD. (2014) Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group. Crit Rev Oncol Hematol 91(1):35–46
18. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25(25):3859–3865
19. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ, Team Hs (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 9555:29–36
20. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WTW, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ (2010) Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. J Clin Oncol 28(21):3422–3428. doi:10.1200/jco.2009.26.0463
21. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen ZZ, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R, Herceptin Adjuvant (HERA) Trial Study Team (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12(3):236–244. doi:10.1016/s1470-2045(11)70033-x
22. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Kohne C-H, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J, Herceptin Adjuvant (HERA) Trial Study Team (2013) T 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 382 (9897):1021–1028.
23. de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM (2014) Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1–01). J Clin Oncol. 32 (20):2159–2165.
24. Inoue K, Nakagami K, Mizutani M, Hozumi Y, Fujiwara Y, Tsukamoto F, Saito M, Miura S, Eguchi K, Shinkai T, Ando M, Watanabe T, Masuda N, Ohashi Y, Sano M, Noguchi S (2010) Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: The JO17360 Trial Group. Breast Cancer Res Treat 119(1):127–136. doi:10.1007/s10549-009-0498-7
25. Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL, Penault-Llorca F (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27(36):6129–6134. doi:10.1200/jco.2009.23.0946
26. Pivot X, Romieu G, Debled M, Pierga J-Y, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin J-P, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A (2013) 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 14(8):741–748. doi:10.1016/s1470-2045(13)70225-0
27. Pivot X, Gligorov J, Mueller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L, PrefHer Study G (2014) Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol 25(10):1979–1987. doi:10.1093/annonc/mdu364
28. de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA, Jr., Kim S-B, Kuemmel S, Huang C-S, Vuylsteke P, Hsieh R-K, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J (2014) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 15 (10):1137–1146.
29. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF (2011) Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer (0008543X) 117(1):39–47. doi:10.1002/cncr.25399
30. Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, Forster JK, Rubin SD, Stein SH, Burstein HJ (2009) Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 20(6):1026–1031. doi:10.1093/annonc/mdn759
31. Burstein HJ, Storniolo AM, Franco S, Forster J, Stein S, Rubin S, Salazar VM, Blackwell KL (2008) A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19(6):1068–1074. doi:10.1093/annonc/mdm601
32. Cristofanilli M, Johnston SRD, Manikhas A, Gomez HL, Gladkov O, Shao Z, Safina S, Blackwell KL, Alvarez RH, Rubin SD, Ranganathan S, Redhu S, Trudeau ME (2013) A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat. 137 (2):471–482.
33. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, Ng C, Franco SX, Chow LW, Arbushites MC, Casey MA, Berger MS, Stein SH, Sledge GW (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26(18):2999–3005
34. Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, DeSilvio M, Westlund R, Zaks T, Spector N, Johnston S (2009) Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 10(6):581–588. doi:10.1016/S1470-2045%2809%2970087-7
35. Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM (2013) Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 14(1):88–96. doi:10.1016/s1470-2045(12)70508-9
36. Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im S-A, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25–32
37. Spector NLBK (2009) Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 27(34):5838–5847
38. Lacouture ME, Laabs SM, Koehler M, Sweetman RW, Preston AJ, Di Leo A, Gomez HL, Salazar VM, Byrne JA, Koch KM, Blackwell KL (2009) Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 114(3):485–493. doi:10.1007/s10549-008-0020-7
39. Fromme EEK, Mori M, Hsieh Y, Beer T (2004) How Accurate Is Clinician Reporting of Chemotherapy Adverse Effects? A Comparison With Patient-Reported Symptoms From the Quality-of-Life Questionnaire C30. J Clin Oncol 22(17):3485–3490
40. Guglin M, Hartlage G, Reynolds C, Chen R, Patel V (2009) Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Card Fail 15(8):651–657. doi:10.1016/j.cardfail.2009.04.011
41. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, Nolè F, Veglia F, Cipolla CM (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28(25):3910–3916. doi:10.1200/jco.2009.27.3615
42. Baselga J, Carbonell X, Castaneda-Soto N-J, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P (2005) Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule. J Clin Oncol 23(10):2162–2171
43. Horiguchi H, Yasunaga H, Hashimoto H, Matsuda S (2011) Incidence of Severe Adverse Events Requiring Hospital Care after Trastuzumab Infusion for Metastatic Breast Cancer: A Nationwide Survey using an Administrative Claim Database. Breast J 17(6):683–685. doi:10.1111/j.1524-4741.2011.01170.x
44. Keefe DMK, Bateman EH (2012) Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol 9:98–109
45. Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L (2013) Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol 14(10):962–970. doi:10.1016/s1470-2045(13)70383-8
46. Azim HA, Jr., Agbor-Tarh D, Bradbury I, Dinh P, Baselga J, Di Cosimo S, Greger JG, Jr., Smith I, Jackisch C, Kim S-B, Aktas B, Huang C-S, Vuylsteke P, Hsieh RK, Dreosti L, Eidtmann H, Piccart M, de Azambuja E (2013) Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.[Erratum appears in J Clin Oncol. 2014 Feb 1;32(4):365]. J Clin Oncol. 31 (36):4504–4511.
47. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML, Harris J, Westlund RE, Salazar V, Zaks TZ, Spector NL (2008) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26(7):1066–1072
48. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 30 (21):2585–2592.